Lexicon Pharmaceuticals (LXRX) Tops Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
Revenue Growth %: -78.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $355 thousand versus the consensus estimate of $320 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
